NOV 17, 202668 MINS READ
Creatine phosphate (CrP), also known as phosphocreatine, represents a phosphorylated derivative of creatine bearing a high-energy N-phosphoryl bond. The molecular formula is C₄H₁₀N₃O₅P with a molecular weight of approximately 211.11 g/mol 1. This compound exists as a zwitterion under physiological pH, contributing to its solubility profile and membrane permeability characteristics 12,15.
The chemical stability of creatine phosphate presents significant handling challenges. Historically, CrP was considered extremely temperature-sensitive and prone to rapid hydrolysis under acidic conditions 1. However, systematic investigation has revealed that creatine phosphate can withstand heating at 80–90°C for up to 10 minutes in weakly alkaline environments (pH 7.5–8.5) without perceptible degradation 1. This thermal tolerance window is critical for enzymatic synthesis termination and purification protocols.
Key Stability Parameters:
The acid-sensitivity of phosphocreatine precludes conventional isolation methods used for nucleotides or sugar phosphates, such as ion-exchange chromatography or activated charcoal adsorption, as even brief acidification results in substantial losses 1. Modern handling protocols therefore emphasize maintenance of alkaline conditions throughout synthesis, purification, and storage phases.
The enzymatic preparation of creatine phosphate offers significant advantages over chemical synthesis in terms of stereochemical purity, reaction selectivity, and environmental sustainability. The primary enzymatic route involves the creatine phosphokinase (CPK, also termed creatine kinase) catalyzed transfer of phosphate from a donor substrate to creatine 1,6.
A well-established method employs 3-phosphoglyceric acid as the phosphate donor in the presence of aqueous muscle extract containing endogenous creatine phosphokinase 1. The reaction proceeds optimally under the following conditions:
This approach achieves near-quantitative conversion and simplifies downstream purification by thermal inactivation of enzymatic components. The surprising thermal stability of CrP in alkaline conditions enables this heat-treatment step, which was previously considered incompatible with phosphocreatine handling 1.
While 3-phosphoglyceric acid serves as an effective phosphate donor, alternative systems have been explored to optimize cost-efficiency and reaction kinetics. Direct phosphorylation using ATP as the phosphate donor, coupled with ATP regeneration systems employing creatine phosphate itself, creates a paradoxical but functional cycle when initiated with catalytic ATP quantities 5,16.
In cell-free protein synthesis (CFPS) systems, creatine phosphate functions as a secondary energy source, donating phosphate to ADP for ATP regeneration 16. However, this leads to phosphate accumulation as a reaction byproduct, necessitating periodic adjustment of energy charge through addition of phosphate-free energy sources such as glucose or dextran combined with exogenous phosphate sources (potassium phosphate, magnesium phosphate) and cyclic AMP (0.05–5.0 mM) 16.
The therapeutic utility of creatine phosphate is fundamentally limited by its poor membrane permeability due to the charged phosphate moiety. Multiple formulation strategies have been developed to overcome this barrier and enhance intracellular delivery.
A sophisticated approach involves synthesis of membrane-permeable prodrugs wherein the phosphate group is masked through esterification or other reversible modifications 2,3,4. These prodrugs are designed to:
Patent literature describes compounds of Formula (I), (II), and (III) incorporating salicyl alcohol moieties, cyclic structures, and other lipophilic groups that enhance membrane permeability while maintaining the capacity for intracellular phosphate release 2,3,4. These prodrugs have demonstrated efficacy in treating ischemia, heart failure, and neurodegenerative disorders in preclinical models 2,3,4.
Controlled-release formulations address the rapid clearance and urinary excretion of creatine and creatine phosphate following oral administration 17. Conventional creatine supplementation produces sharp plasma concentration spikes followed by rapid decline, with substantial urinary losses 17.
Design Principles For Controlled Delivery:
Nutritional compositions combining creatine phosphate with compounds that enhance cellular uptake represent another strategic approach 5,7,8,9. Key components include:
Creatinol-O-phosphate, a hydroxylated analog, has been incorporated into timed-release formulations (0.5–5 g per serving, preferably 1.5 g twice daily) for its purported role in ATP synthesis enhancement and hydrogen ion buffering during intense muscular exercise 7,8,9.
Accurate quantification of creatine phosphate in biological samples, pharmaceutical formulations, and research preparations requires specialized analytical techniques that account for the compound's lability and the presence of interfering substances.
The most sensitive method for CrP determination exploits the creatine kinase reaction coupled to luciferase-based ATP detection 14. The assay protocol involves:
This method achieves picomolar sensitivity and shows excellent correlation (r > 0.95) with spectrophotometric reference methods while requiring minimal sample volume 14.
Traditional spectrophotometric methods monitor NADH oxidation or formation in coupled enzyme systems. For creatine kinase activity determination in the presence of CrP, the reaction sequence typically involves:
The decrease in NADH absorbance at 340 nm is proportional to creatine kinase activity and, indirectly, to CrP concentration 14. While less sensitive than bioluminescence methods, spectrophotometric assays provide robust quantification suitable for quality control applications.
High-performance liquid chromatography (HPLC) and ion-exchange chromatography can separate creatine phosphate from creatine, ATP, ADP, and other phosphorylated metabolites. However, the acid-sensitivity of CrP necessitates careful pH control throughout the analytical procedure 1. Anion-exchange chromatography with alkaline mobile phases (pH 8.0–9.0) and UV detection at 210–214 nm enables simultaneous quantification of multiple energy metabolites in tissue extracts.
Creatine phosphate has demonstrated significant therapeutic potential in cardiovascular disorders characterized by energy metabolism dysfunction, particularly in conditions involving ischemia and impaired ATP regeneration.
A novel therapeutic approach combines exogenous creatine phosphate with creatine phosphokinase for treatment of atherosclerotic plaques 6. The rationale is based on observations that atherosclerotic tissue exhibits marked ischemia, hypoxia, and reduced enzymatic activity, resulting in severely depleted ATP and CrP levels within plaques 6.
Mechanistic Basis:
Clinical protocols typically involve intravenous administration of CrP (1–2 g per dose) in combination with CPK enzyme, though optimal dosing regimens and treatment duration remain subjects of ongoing investigation 6.
Creatine phosphate administration has been explored for myocardial protection during cardiac surgery, percutaneous coronary intervention, and acute myocardial infarction. The compound's ability to rapidly regenerate ATP in energy-depleted cardiomyocytes may limit infarct size and preserve ventricular function 2,4.
Membrane-permeable CrP prodrugs offer particular promise in this context, as they can be administered orally or intravenously and achieve intracellular concentrations sufficient to support ATP regeneration during critical ischemic periods 2,4. Preclinical studies have demonstrated reduced markers of myocardial injury and improved hemodynamic parameters following CrP prodrug administration in animal models of coronary occlusion 2,4.
The central nervous system exhibits high and fluctuating energy demands, making neurons particularly vulnerable to ATP depletion. Creatine phosphate and related compounds have shown remarkable neuroprotective effects across multiple experimental models of neurological disease.
Creatine compounds, including creatine phosphate, cyclocreatine, and β-guanidinopropionic acid, mediate neuroprotection through several interconnected mechanisms 11,18:
Amyotrophic Lateral Sclerosis (ALS): Creatine and creatine phosphate analogs have demonstrated efficacy in experimental ALS models, potentially slowing motor neuron degeneration through energy metabolism support 11,18.
Huntington's Disease: Oral creatine administration increases brain creatine and phosphocreatine levels, improving motor function and extending survival in transgenic mouse models 10,11.
Parkinson's Disease: Creatine supplementation may protect dopaminergic neurons from oxidative damage and energy depletion, though clinical trial results have been mixed 10,11.
Traumatic Brain Injury: Acute creatine phosphate administration following experimental brain trauma reduces lesion volume and improves functional outcomes, likely through preservation of cellular energy status during the critical post-injury period 10,11.
Stroke And Cerebral Ischemia: CrP prodrugs capable of crossing the blood-brain barrier show promise for acute neuroprotection during ischemic stroke, maintaining neuronal ATP levels and reducing infarct expansion 2,11.
Transmissible Spongiform Encephalopathies: Emerging evidence suggests creatine compounds may offer protective effects against prion-mediated neurodegeneration, potentially through maintenance of cellular energy homeostasis and inhibition of prion protein misfolding cascades 18.
Typical dosing for neuroprotective applications ranges from 5–20
| Org | Application Scenarios | Product/Project | Technical Outcomes |
|---|---|---|---|
| XENOPORT INC. | Treatment of ischemia, heart failure, and neurodegenerative disorders requiring intracellular ATP regeneration and energy metabolism support. | Membrane Permeable Creatine Phosphate Prodrugs | Enhanced cellular uptake through membrane-permeable prodrug design that releases active creatine phosphate intracellularly, overcoming the poor membrane permeability of charged phosphate moiety. |
| BOEHRINGER MANNHEIM GMBH | Large-scale pharmaceutical production and research applications requiring high-purity creatine phosphate with simplified purification through thermal enzyme denaturation. | Enzymatic Creatine Phosphate Synthesis Process | Achieves near-quantitative conversion using creatine phosphokinase with 3-phosphoglyceric acid as phosphate donor; withstands heating at 80-90°C for enzyme inactivation without creatine phosphate degradation in alkaline conditions (pH 7.5-8.5). |
| Northwestern University | Biotechnology applications requiring cell-free protein production systems with optimized energy metabolism and extended reaction duration. | Cell-Free Protein Synthesis (CFPS) System | Utilizes creatine phosphate as secondary energy source for ATP regeneration, maintaining Energy Charge at 0.80-1.0 levels; enables sustained protein synthesis through substrate replenishment and phosphate management. |
| ARTCELL INVEST LTD. | Treatment of atherosclerotic plaques characterized by severe ischemia, hypoxia, and depleted energy metabolism requiring biochemical reactivation. | Creatine Phosphate-CPK Combination Therapy | Provides exogenous high-energy phosphate and enzyme to reactivate depleted ATP and cAMP levels in ischemic atherosclerotic plaques; chemically more stable than ATP and avoids negative inotropic effects at high concentrations. |
| APLODAN FORMULATIONS LTD. | Sports nutrition and muscle performance enhancement applications requiring sustained energy delivery and acid buffering during high-intensity intermittent exercise. | Creatinol-O-Phosphate Timed-Release Formulation | Delivers 0.5-5g creatinol-phosphate (preferably 1.5g twice daily) via controlled-release system; enhances ATP synthesis and acts as hydrogen ion buffer during intense muscular exercise, increasing endurance before fatigue onset. |